Kura Oncology (Nasdaq: KURA) announced that on March 2, 2026 the Compensation Committee granted inducement nonstatutory stock options to four new employees totaling 44,700 shares under the company’s 2023 Inducement Option Plan, as amended.
Each option has an exercise price of $8.68 (closing price on March 2, 2026) and vests over four years: 25% after one year and the remainder monthly over 36 months, subject to continued service and plan terms.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – KURA
+5.29%
9 alerts
+5.29%Session close to close
$780.11MMarket Cap
1.1xRel. Volume
In the Mar 6 session, KURA gained 5.29%, reflecting a notable positive market reaction.
Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with Kur...
Analysis
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with Kura’s pattern of investors sometimes rewarding routine corporate updates, as seen with prior inducement grants that preceded a 5.81% move. However, the stock already traded 31.87% below its 52-week high with elevated volume at 2.04x average, so gains could be sensitive to shifts in sentiment, insider activity trends, or follow‑on news about commercialization and pipeline progress.
Key Figures
Inducement options:44,700 sharesExercise price:$8.68 per shareNew employees:4 employees+4 more
7 metrics
Inducement options44,700 sharesNonstatutory stock options granted to four new employees
Exercise price$8.68 per shareEqual to closing price on March 2, 2026
New employees4 employeesRecipients of inducement stock option awards
Initial vesting cliff25% after one yearOne-year anniversary of vesting commencement date
Remaining vesting period36 monthsMonthly vesting of remaining options after first year
Total vesting durationFour yearsStandard vesting schedule for inducement options
Grant dateMarch 2, 2026Date Compensation Committee approved inducement awards
KOMZIFTI approval, early revenues, milestone payments and 2026 development priorities.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive fundamental updates have sometimes seen negative price reactions, while neutral or routine updates, including prior inducement grants, have occasionally coincided with gains.
Recent Company History
Over recent months, Kura transitioned into a commercial-stage company with KOMZIFTI FDA approval and early revenue contributions. Earnings on Mar 5, 2026 highlighted $667.2M cash and collaboration support, yet the stock fell 0.47%. Earlier, milestone and revenue updates on Jan 11 saw a 2.55% decline. By contrast, neutral events like conference participation and a prior inducement grant on Feb 6 aligned with gains, underscoring mixed reactions to fundamentally positive news.
"granted inducement awards consisting of nonstatutory stock options... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
nonstatutory stock optionsfinancial
"granted inducement awards consisting of nonstatutory stock options to purchase 44,700 shares"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
exercise pricefinancial
"Each stock option has an exercise price equal to $8.68 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement datefinancial
"on the one-year anniversary of the applicable vesting commencement date and the balance"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
stock option agreementfinancial
"subject to the terms and conditions of an applicable stock option agreement covering the grant."
A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.
inducement option planfinancial
"to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended."
A plan that grants stock options to newly hired or newly promoted employees and executives as a hiring or retention incentive, like offering a share of future upside instead of a higher salary. For investors this matters because these options can dilute existing shares, create ongoing compensation costs, and signal how management is being incentivized to grow the business—similar to giving a performance-based bonus that ties pay to company results.
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 44,700 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to $8.68 per share, the closing price of the Company’s common stock on March 2, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
What did KURA announce about inducement option grants on March 2, 2026?
Kura granted nonstatutory stock options totaling 44,700 shares to four new employees as inducement awards. According to the company, the grants were made under the 2023 Inducement Option Plan and approved under Nasdaq Listing Rule 5635(c)(4).
What is the exercise price and vesting schedule for the KURA inducement options?
Each option carries an $8.68 exercise price, equal to the March 2, 2026 closing price. According to the company, options vest 25% after one year and the balance vests monthly over the following 36 months, subject to continued service.
How many employees received inducement awards in KURA's March 2026 grants?
The Compensation Committee granted inducement options to four new employees, totaling 44,700 underlying shares. According to the company, the awards were approved as material inducements to employment under Nasdaq rules.
Under which plan were KURA's March 2026 inducement options issued?
The options were issued under the company’s 2023 Inducement Option Plan, as amended. According to the company, each option is also subject to an applicable stock option agreement and the plan’s terms and conditions.
Will KURA's inducement option grants dilute existing shareholders and when do they vest?
The grants total 44,700 shares and will vest over four years, with 25% after one year and monthly vesting thereafter. According to the company, vesting is subject to continued service; dilution impact depends on total shares outstanding.
